A Pre-Conference Program; additional registration was required
While many patients with cancer are experiencing significant long-term benefits from immune checkpoint inhibitors (ICIs), the vast majority exhibit either primary or secondary (acquired) resistance to these therapies. The underlying mechanisms for the wide range of responses are not well understood. Before ICI resistant/relapsed patients can be properly managed, however, these underlying causes need to be elucidated, which will enable rational design of therapeutic options based on these mechanisms of resistance. Testing of therapies in this ICI-resistant population also presents unique questions, including defining resistance and proper clinical trial design strategies.
Addressing the problem of ICI resistance and failure therefore will require collaboration between researchers and clinicians involved in all aspects of cancer research and practice, including basic, translational, and clinical areas. This program will featured both invited faculty presentations by experts in the field, as well as abstract presentations from researchers, who applied for consideration for oral presentation. These presentations were interspersed throughout the program. Session topics included defining immune checkpoint inhibitor resistance, primary resistance, secondary/acquired resistance, and therapeutic strategies for patients with resistant disease. This workshop brought together all stakeholders to address ICI resistance and failure, in order to move the field forward and continue advancing patient care.
This session used the work of the SITC Immunotherapy Resistance Committee as a foundation for discussion. The multi-stakeholder Committee has recently generated expert clinical definitions of PD-(L)1 inhibitor resistance, published in the JITC manuscript “Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce."
Monday, Nov. 9, 2020*
9 a.m. - 3:15 p.m. EST
*Dates and times subject to change.
- Kald Abdallah, MD, PhD – Bristol Myers Squibb
- Edward Cha, MD, PhD – Genentech
- Jennifer Gansert, MD, PhD – Amgen
- Israel Lowy, MD, PhD – Regeneron Pharmaceuticals
- Giovanni Melillo, MD – AstraZeneca
- Eric Rubin, MD – Merck & Co., Inc.
SITC's Immunotherapy Resistance and Failure is supported in part by grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member if the Roche Group, Incyte Corporation, and Kite, a Gilead Company.
*Program schedule subject to change.